Very much looking forward to the upcoming final Results of data in part c in head and neck cancer,in the coming week or so.Any improvement in this very hard to treat patient group would be a very big deal.Potentially setting the platform for near term accelerated approval.
Efti received FDA Fast Track designation in 1L HNSCC on strength of the clinical results from TACTI-002 trial (Part C) in 2L HNSCC including:
5 Complete Responses for a CR rate of 13.5% vs 1.6% for pembrolizumab
Durable, deep responses with median DoR not yet reached and minimum duration of 9+ months
”Accelerated approval based on TACTI-003 results in play. Clearly dependent on the results of this Phase IIb trial,”
Overnight Market report, page-1795
-
- There are more pages in this discussion • 1,135 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
-0.010(3.51%) |
Mkt cap ! $400.0M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.3¢ | 27.0¢ | $1.034M | 3.758M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 98156 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 85523 | 9 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |